“The Value and Sustainability of Ocrelizumab in Relapsing Multiple Sclerosis: A Cost-Effectiveness and Budget Impact Analysis”, FE, vol. 20, no. 1, Jul. 2019, doi: 10.7175/fe.v20i1.1435.